Piper Sandler analyst Adam Maeder raised the firm’s price target on Nyxoah to $20 from $15 and keeps an Overweight rating on the shares. The firm notes Nyxoah reported Q4 revenues in-line with the January pre-announcement and nicely ahead of consensus. Management attributed the uptick in top-line growth to sustained demand for Genio and continued penetration into the German market along with some early benefit from the company’s DTC initiatives.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NYXH:
- Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
- Is NYXH a Buy, Before Earnings?
- Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
- Nyxoah price target raised to $18 from $15 at H.C. Wainwright
- Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
